STOCK TITAN

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:40 a.m. ET. The presentation by Arthur T. Sands, M.D., Ph.D., the company's president and CEO, will be available via webcast on the Nurix website in the Investors section. The archived webcast will be accessible for 30 days post-event. Nurix, a clinical-stage biopharmaceutical company, focuses on developing targeted protein modulation drugs for cancer treatment. Its proprietary platform, DELigase, aids in discovering novel drug candidates targeting E3 ligases.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will provide a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference (Virtual) on Tuesday, March 14 at 10:40 a.m. ET.

The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Silinda Neou
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com


FAQ

What is the date and time of Nurix Therapeutics' presentation at the Oppenheimer Healthcare Conference?

Nurix Therapeutics' presentation is scheduled for March 14, 2023, at 10:40 a.m. ET.

Where can I access the live webcast of the Nurix Therapeutics presentation?

The live webcast of the Nurix Therapeutics presentation can be accessed via the Investors section of the Nurix website.

How long will the archived webcast of the Nurix presentation be available?

The archived webcast of the Nurix presentation will be available for 30 days after the event.

What is the focus of Nurix Therapeutics as a biopharmaceutical company?

Nurix Therapeutics focuses on developing targeted protein modulation drugs to treat hematologic malignancies and solid tumors.

Who is presenting at the Oppenheimer Healthcare Conference for Nurix Therapeutics?

Arthur T. Sands, M.D., Ph.D., the president and CEO of Nurix Therapeutics, will present at the conference.

Nurix Therapeutics, Inc.

NASDAQ:NRIX

NRIX Rankings

NRIX Latest News

NRIX Stock Data

1.40B
69.46M
1.45%
98.43%
13.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO